Elizabeth Jungman, J.D., M.P.H., serves as CDER’s Associate Director for Policy and Director of the Office of Regulatory Policy (ORP). Ms. Jungman serves as the Center’s primary representative for broad policy matters and issues related to human drugs. She advises the Center Director and FDA officials on all matters involving drug policy development, execution, and long-range program goals. This includes providing counsel on industry positions and proposals, precedent cases, proposed legislation, and the implementation of regulations and standards related to drugs. Ms. Jungman helps oversee the development of regulations, policies, and procedures that affect nearly every aspect of CDER.
She is a nationally recognized expert in drug regulatory policy. Before joining CDER, she was the Director of Public Health Programs at the Pew Charitable Trusts. She has also served as Senior Health Policy Adviser with the U.S. Senate Committee on Health, Education, Labor, and Pensions, where she played a crucial role in drafting and negotiating the Food and Drug Administration Safety and Innovation Act of 2012 and other health- and drug-related legislation, including, pandemic preparedness, drug compounding, and supply chain security.
Ms. Jungman earned her bachelor’s degree in biology from Harvard College, law degree from Georgetown University, and a master’s degree in public health from Johns Hopkins.